Eli Lilly and Company (LLY) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.

Total Revenue Chart for Eli Lilly and Company

Eli Lilly and Company (LLY) revenue for FY2025 was USD 65.2B, a 44.7% change from FY2024. Eli Lilly and Company's revenue grew from USD 3.3B in 1985 to USD 65.2B in 2025 (1892.9% over 40 years). Earnings per share grew from USD 2.79 in 2000 to USD 22.98 in 2025 (723.8%). Revenue compound annual growth rate: 5-year CAGR of 21.6%, 10-year CAGR of 12.6%, 20-year CAGR of 7.8%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.06T
Implied Share Price
$1191.94
Enterprise Value
$1.03T
Revenue (TTM)
$79.67B
EBITDA
$41.68B
Profit Margin
33.53%
Trailing P/E
39.22
Forward P/E
32.89
Price/Book (MRQ)
31.89
Price/Sales (TTM)
13.34
EV/EBITDA
28.52
EV/Revenue
14.30
Dividend Yield
0.55%
Book Value
$34.92
Free Cash Flow (FY2025)
$8.97B
Free Cash Flow Yield
0.84%

Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.